Merck: drug approved for prostate cancer
(CercleFinance.com) - AstraZeneca and MSD (Merck & Co outside North America) announce that their drug Lynparza has been approved by the US FDA for metastatic castration-resistant prostate cancer with HRR gene mutation.
This decision was based on the results of a phase III trial that showed a strong reduction in the risk of disease progression and a clinically and statistically significant improvement in overall survival.
Following this approval in the US, AstraZeneca will receive a regulatory milestone payment of 35 million dollars from MSD, which is expected to be recognised in its collaboration revenues in the second quarter of 2020.
Copyright (c) 2020 CercleFinance.com. All rights reserved.